Reported 2 months ago
Amgen's Chief Financial Officer, Peter Griffith, expressed confidence in the company's weight-loss drug MariTide during a recent interview. As the drug progresses through trials, Griffith highlighted Amgen's plans for a broad phase three program, noting significant increases in research and development spending. MariTide aims to differentiate itself by offering less frequent dosing compared to competitors, with a focus on treating obesity and related conditions like chronic kidney disease and cardiovascular disease.
Source: YAHOO